Table 2.
Association of PRMT6 methylation with clinical characteristics in CRC patients
| Variables | N | Tumor PMR (%) | P value | Para‐tumor PMR (%) | P value |
|---|---|---|---|---|---|
| Total | 121 | 36.93 (19.89, 65.95) | 63.12 (37.01, 119.50) | ||
| Gendera | |||||
| Male | 80 | 41.37 (20.43, 70.80) | .553 | 67.08 (41.24, 120.30) | .198 |
| Female | 39 | 34.97 (18.96, 56.38) | 61.56 (16.52, 120.50) | ||
| Age (y)a | |||||
| ≤65 | 78 | 33.15 (19.38, 59.63) | .097 | 64.33 (41.41, 146.58) | .114 |
| >65 | 41 | 51.77 (21.84, 92.10) | 55.05 (20.19, 101.24) | ||
| Differentiationa | |||||
| poorly | 17 | 40.55 (12.73, 66.66) | .653 | 51.97 (38.80, 108.48) | .032 |
| moderate + well | 101 | 36.93 (21.81, 69.09) | 64.12 (36.81, 120.70) | ||
| Tumor sizea | |||||
| ≤5 cm | 80 | 36.92 (23.52, 67.80) | .563 | 55.29 (41.24, 106.53) | .210 |
| >5 cm | 40 | 38.52 (14.6, 65.04) | 87.96 (33.9, 128.32) | ||
| Lymphatic metastasisa | |||||
| Yes | 56 | 31.49 (13.95, 56.61) | .235 | 67.53 (41.80, 146.12) | .442 |
| No | 63 | 47.24 (21.96, 77.17) | 57.21 (35.77, 111.7) | ||
PMR, the percentage of methylated reference.
Data are presented as median (interquartile range).
P value is calculated by Spearman test. Two‐sided P value < .05 (in bold).
a
A small amount (<1%) of patients did not have the information.